317 related articles for article (PubMed ID: 10916759)
21. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
22. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
23. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
Berard F; Blanco P; Davoust J; Neidhart-Berard EM; Nouri-Shirazi M; Taquet N; Rimoldi D; Cerottini JC; Banchereau J; Palucka AK
J Exp Med; 2000 Dec; 192(11):1535-44. PubMed ID: 11104796
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.
Lau R; Wang F; Jeffery G; Marty V; Kuniyoshi J; Bade E; Ryback ME; Weber J
J Immunother; 2001; 24(1):66-78. PubMed ID: 11211150
[TBL] [Abstract][Full Text] [Related]
25. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF
Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766
[TBL] [Abstract][Full Text] [Related]
26. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
27. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
[TBL] [Abstract][Full Text] [Related]
28. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
[TBL] [Abstract][Full Text] [Related]
29. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Butterfield LH; Ribas A; Dissette VB; Amarnani SN; Vu HT; Oseguera D; Wang HJ; Elashoff RM; McBride WH; Mukherji B; Cochran AJ; Glaspy JA; Economou JS
Clin Cancer Res; 2003 Mar; 9(3):998-1008. PubMed ID: 12631598
[TBL] [Abstract][Full Text] [Related]
30. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
31. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells.
Prabakaran I; Menon C; Xu S; Gómez-Yafal A; Czerniecki BJ; Fraker DL
Ann Surg Oncol; 2002 May; 9(4):411-8. PubMed ID: 11986195
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
34. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M
J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150
[TBL] [Abstract][Full Text] [Related]
36. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
Ribas A; Glaspy JA; Lee Y; Dissette VB; Seja E; Vu HT; Tchekmedyian NS; Oseguera D; Comin-Anduix B; Wargo JA; Amarnani SN; McBride WH; Economou JS; Butterfield LH
J Immunother; 2004; 27(5):354-67. PubMed ID: 15314544
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
39. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
[TBL] [Abstract][Full Text] [Related]
40. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]